Moderna stock soared 5.35% in pre-market trading on Monday, following a significant announcement from the U.S. Food and Drug Administration (FDA). The regulatory body has approved Moderna's next-generation Covid-19 vaccine for adults aged 65 or older, marking a crucial milestone for the biotechnology company.
The FDA's decision to greenlight Moderna's updated Covid vaccine for the elderly population underscores the continued importance of coronavirus protection, particularly for vulnerable age groups. This approval could potentially boost Moderna's revenue streams and market position in the ongoing fight against Covid-19 variants. The company's ability to adapt its vaccine technology to address evolving health challenges appears to have resonated positively with investors.
Despite the pre-market rally, it's worth noting that analyst sentiment remains cautious. Barclays analyst Gena Wang recently maintained a Hold rating on Moderna with a price target of $40.00. This suggests that while the FDA approval is a positive development, broader market factors and the company's overall performance continue to influence expert opinions. Investors will likely be watching closely to see if this pre-market momentum translates into sustained gains during regular trading hours.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。